News & Events
[return to all news & events]
BioCentury, May 25, 2009
Altair Therapeutics Inc., San Diego, CAlif.
Isis Pharmaceuticals inc. (NASDAQ:ISIS), Carlsbad, Calif.
Product: AIR645 (formerly ISIS 369645)
Business: Inflammation
Molecular target: Interleukin-4 (IL-4) receptor (CD 124); Interleukin-13 (IL-13)
Description: Inhaled inhibitor of the interleukin-4/interleukin-13 (IL-4/IL-13) signaling pathways
Indication: Treat asthma
Endpoint: Safety
Status: Phase I data
Milestone: Start Phase II (2H09)
Data from a double-blind, placebo-controlled, single and multiple dose, Canadian Phase I trial (AIR645-CSI) in 72 evaluable healthy volunteers showed that nebulized AIR645 was well tolerated and had dose-dependent exposure in the airways. The single doses ranged from 0.03-30 mg and multiple doses ranged from 0.3-20mg. No serious adverse events or dose-limiting toxicities were observed. The trial has enrolled 80 subjects, including 8 asthma patients. Data were presented at the American Thoracic Society meeting in San Diego. Isis granted Altair exclusive rights to the product in 2007 (see BioCentury, Oct. 22, 2007).